{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:47:28Z","timestamp":1785822448692,"version":"3.56.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-glutamic acid decarboxylase 65 (GAD65) antibody-associated neurological syndrome is a rare autoimmune disorder with heterogeneous clinical manifestations, including epilepsy and cerebellar ataxia. Standard treatment strategies remain limited. This report aimed to describe a rare case presenting with combined epilepsy and cerebellar ataxia, and to evaluate the efficacy of efgartigimod followed by mycophenolate mofetil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We present a 62-year-old female with slowly progressive recurrent epileptic seizures and cerebellar ataxia. Clinical, neurological, neuroimaging (PET\/CT, MRI), and laboratory examinations (serum and cerebrospinal fluid GAD65 antibodies) were analyzed. The patient was treated with efgartigimod (10 mg\/kg weekly for 3 doses) plus maintenance mycophenolate mofetil. Clinical outcomes and follow-up data were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Neurological examination showed left-sided dysmetria, dysdiadochokinesia, and a positive Romberg sign. Brain PET\/CT revealed hypometabolism in the bilateral temporal lobes, right hippocampus, and left frontoparietal regions, accompanied by mild right hippocampal atrophy. Serum and cerebrospinal fluid (CSF) examinations were positive for GAD65 antibodies at titers of 1:1000 and 1:100, respectively, confirming the diagnosis of GAD65 antibody-associated neurological syndrome. After treatment, seizures completely resolved, gait ataxia improved significantly, and daily activities were fully restored at 1-month follow-up. Antiseizure medications were gradually tapered. No clinical relapse occurred during the 1-year follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case demonstrates that anti-GAD65 antibody syndrome can present as concurrent refractory epilepsy and cerebellar ataxia. The sequential regimen of efgartigimod induction combined with mycophenolate mofetil maintenance appears effective and safe. This therapeutic strategy may provide a valuable reference for the clinical management of such rare autoimmune neurological disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1849117","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:38:33Z","timestamp":1785821913000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of anti-GAD65 antibody-positive epilepsy and cerebellar ataxia with efgartigimod: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Lulu","family":"Xie","sequence":"first","affiliation":[{"name":"Tianjin Academy of Traditional Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqin","family":"Zuo","sequence":"additional","affiliation":[{"name":"First Department of Neurology, North China University of Science and Technology Affiliated Hospital","place":["Tangshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Neurology II, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology II, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology II, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Academy of Traditional Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunying","family":"Deng","sequence":"additional","affiliation":[{"name":"Tianjin Academy of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"First Department of Neurology, North China University of Science and Technology Affiliated Hospital","place":["Tangshan, China"]},{"name":"Department of Neurology II, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/mus.25565","article-title":"GAD65 neurological autoimmunity","volume":"56","author":"McKeon","year":"2017","journal-title":"Muscle Nerve"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325275","article-title":"Clinical spectrum of high-titre GAD65 antibodies","volume":"92","author":"Budhram","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09807-2","article-title":"Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies","volume":"267","author":"Joubert","year":"2020","journal-title":"J Neurol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000696","article-title":"Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment","volume":"7","author":"Munoz-Lopetegi","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12311-024-01768-w","article-title":"Glutamic acid decarboxylase 65 antibody-associated epilepsy and diplopia: Two case reports with literature review","volume":"24","author":"Chen","year":"2024","journal-title":"Cerebellum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387591","article-title":"Clinical features in antiglycine receptor antibody-related disease: a case report and update literature review","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103701","article-title":"Neurological syndromes associated with anti-GAD antibodies","volume":"21","author":"Dade","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.01.021","article-title":"Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy","volume":"80","author":"Daif","year":"2018","journal-title":"Epilepsy Behav"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0359-x","article-title":"GAD antibodies in neurological disorders - insights and challenges","volume":"16","author":"Graus","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16571","article-title":"Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions","volume":"61","author":"Steriade","year":"2020","journal-title":"Epilepsia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16282","article-title":"Seizure specificities in patients with antibody-mediated autoimmune encephalitis","volume":"60","author":"Vogrig","year":"2019","journal-title":"Epilepsia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12799","article-title":"Musicogenic reflex seizures in epilepsy with glutamic acid decarbocylase antibodies","volume":"137","author":"Falip","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000696","article-title":"Neurological syndromes and potential triggers associated with antibodies to neuronal surface antigens","volume":"80","author":"Klein da Costa","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.2985","article-title":"Autoimmune epilepsy: clinical characteristics and response to immunotherapy","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12883-015-0435-9","article-title":"Long latency between GAD-antibody detection and development of limbic encephalitis--a case report","volume":"15","author":"Fauser","year":"2015","journal-title":"BMC Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: Real-world evidence from the GENERATE Registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-019-00185-z","article-title":"New-onset refractory status epilepticus with underlying autoimmune etiology: a case report","volume":"2","author":"Brunker","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.990553","article-title":"Neurological disorders associated with glutamic acid decarboxylase 65 antibodies: Clinical spectrum and prognosis of a cohort from China","volume":"13","author":"Bai","year":"2022","journal-title":"Front Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1550023","article-title":"Resolution of anti-GAD-associated autoimmune encephalitis in patients treated with efgartigimod","volume":"16","author":"Chen","year":"2025","journal-title":"Front Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/b978-0-12-814572-2.00003-0","article-title":"Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy","volume":"64","author":"Rajabally","year":"2021","journal-title":"Muscle Nerve"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1849117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:38:34Z","timestamp":1785821914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1849117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1849117"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1849117","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1849117"}}